MDT

Medtronic
D

MDT

Arincen70/100B

Medtronic return on equity (ROE)

Medtronic's return on equity is 10.49%: net income of 5.27B USD over the last twelve months on shareholders' equity of 50.23B USD.

Today
10.49%
Average, 5 years
8.84%
Low, 5 years
7.13%
High, 5 years
10.49%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 5.27B ÷ 50.23B = 10.49%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Medtronic's return on equity?

Net margin
13.2%
profit on each dollar of sales
Asset turnover
0.39×
sales on each dollar of assets
Equity multiplier
1.88×
assets on each dollar of equity
Return on equity
9.7%
FY2026
  • FY202613.2% × 0.39 × 1.88 = 9.7%
  • FY202513.9% × 0.37 × 1.91 = 9.7%
  • FY202411.4% × 0.36 × 1.79 = 7.3%
  • FY202312.0% × 0.34 × 1.77 = 7.3%
  • FY202215.9% × 0.35 × 1.73 = 9.6%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today10.49%5.27B50.23B
FY202624 Apr 20269.78%4.84B49.46B
FY202525 Apr 20259.77%4.69B48.02B
FY202426 Apr 20247.32%3.68B50.21B
FY202328 Apr 20237.35%3.78B51.48B
FY202229 Apr 20229.63%5.06B52.55B
FY202130 Apr 20217.06%3.63B51.43B
FY202030 Apr 20209.47%4.81B50.74B
FY201926 Apr 20199.28%4.65B50.09B
FY201827 Apr 20186.10%3.10B50.72B
FY201728 Apr 20178.00%4.02B50.29B
FY201629 Apr 20166.83%3.54B51.83B
FY201530 Apr 20155.03%2.68B53.23B
FY201425 Apr 201415.76%3.07B19.44B
FY201330 Apr 201318.57%3.47B18.67B
FY201230 Apr 201221.14%3.62B17.11B
FY201130 Apr 201119.39%3.10B15.97B
FY201030 Apr 201021.18%3.10B14.63B
FY200930 Apr 200916.88%2.17B12.85B
FY200830 Apr 200819.34%2.23B11.54B
FY200730 Apr 200725.53%2.80B10.98B
FY200630 Apr 200627.14%2.55B9.38B
FY200530 Apr 200517.26%1.80B10.45B
FY200430 Apr 200421.59%1.96B9.08B
FY200330 Apr 200320.23%1.60B7.91B
FY200230 Apr 200215.30%984.00M6.43B
FY200130 Apr 200118.99%1.05B5.51B
FY200030 Apr 200024.46%1.10B4.49B
FY199930 Apr 199912.42%468.40M3.77B
FY199830 Apr 199829.09%594.60M2.04B
FY199730 Apr 199730.35%530.00M1.75B
FY199630 Apr 199624.47%437.80M1.79B
FY199530 Apr 199522.02%294.00M1.34B
FY199430 Apr 199422.06%232.40M1.05B
FY199330 Apr 199325.15%211.60M841.50M
FY199230 Apr 199220.28%161.50M796.50M
FY199130 Apr 199119.53%133.40M683.20M
FY199030 Apr 199020.09%108.70M541.00M
FY198930 Apr 198920.57%97.40M473.60M
FY198830 Apr 198821.85%86.50M395.90M
FY198730 Apr 198719.07%73.80M387.00M
FY198630 Apr 198615.31%53.40M348.70M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Medtronic's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.